Research

Hormonal

Combination therapies targeting multiple gut hormone pathways (e.g., GLP-1 + Amylin, GLP-1 + GIP, GLP-1 + GIP + Glucagon) show superior weight loss efficacy compared to monotherapies, approaching the magnitude of weight loss seen after bariatric surgery.

For patients who do not achieve sufficient weight loss with single-agent GLP-1 therapy, combination treatments (like CagriSema or Tirzepatide) offer a powerful alternative. These drugs target multiple hormonal pathways simultaneously, resulting in greater weight loss (up to 17% or more in trials) than monotherapies alone. This approach narrows the gap between medication and surgery, offering a viable option for those with severe obesity.

GoodSupportsHIGH confidence
These results highlight the potential of dual agonist therapies, compared to single-target therapies, to enhance weight loss. With weight reductions of 25 % typically observed after bariatric surgery, these results provide assurance of narrowing the treatment gap between pharmacotherapy and bariatric surgery.
Chloe Firman et al. · Proceedings of The Nutrition Society · 2022

Why this rating

Based on Phase 1b/2 trials and preclinical models cited.

Source

A new era in gut hormone-based pharmacotherapy for people with obesity

Chloe Firman et al. · Proceedings of The Nutrition Society · 2022

DOI 10.1017/s0029665122002695

narrative_reviewCited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →